A Randomized Study Evaluating Tailoring of Advanced/Metastatic Colorectal Cancer (CRC) Therapy Using Circulating Cell-Free Tumor DNA (ctDNA) (TACT-D)
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms TACT-D
Most Recent Events
- 28 Jun 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2026.
- 28 Jun 2024 Planned primary completion date changed from 31 Aug 2024 to 31 Aug 2026.
- 04 Jun 2024 Results (Between 4/2019 and 8/2023) assessing early ctDNA changes and clinical utility of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.